Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Should Building Managers Do If COVID Doesn’t Go Away?

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year. There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year.

There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the vaccine isn’t effective, the virus mutates or it returns in different forms, like the flu?

Those possibilities are why everyone, but especially building managers, must ask the question of what we do if COVID doesn’t go away, said John Shanahan, President of Ionogen.

“Maybe it’s a mutation or maybe the flu gets smarter. We have to have more long-term strategies for getting people back into business,” Shanahan said.

Shanahan has found his company’s hypochlorous solutions highly effective in Ionogen’s own office, with none of his team of 50 testing positive for COVID during the pandemic.

“In February, when this really started to ramp up, we deployed all the humidification devices in our building. Because we made surface sanitizers and disinfectants and they were still trying to figure out what COVID was, we put the air sanitizers up as a preventative measure,” he said. “We were so busy February, March, April and May that there was no stopping. But because we have both the physical staff in our manufacturing division and we needed to be able to collaborate, we just added more units into our space.”

Now, they’re looking into the positive results of hypochlorous actually getting into the upper respiratory areas and potentially killing the virus.

“We’re very excited about the future of where this is going to take us. We will continue, as always, to do more testing and trials and the continued research on this,” Shanahan said. “We’re committed to science, and we like proof. Anecdotes are great, and we’ve got a lot of anecdotes about how this has worked up until now. Now, we’ll continue to dig down into the science. Hypochlorous could very well be the antidote without having to take the immunization.”

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

OpenLoop acquires AI communication platform Hey Revia as digital health M&A heats up

OpenLoop acquires AI communication platform Hey Revia as digital health M&A heats up

OpenLoop has acquired AI communication platform Hey Revia as part of growing M&A activity in the digital health sector. The acquisition reflects an ongoing trend in digital health mergers and partnerships, including the announcement of FDA breakthrough status for Aurenar and Sharecare's collaboration with AWS. These developments highlight the increasing investment and strategic alliances shaping the digital health landscape.

  • 01OpenLoop acquires AI communication platform Hey Revia.
  • 02FDA grants Aurenar breakthrough status.
  • 03Sharecare partners with AWS to enhance digital health solutions.

Jul 4, 2026

Healthcare AI governance, data quality, and interoperability top industry agenda in mid-2026

Healthcare AI governance, data quality, and interoperability top industry agenda in mid-2026

The article discusses the challenges faced by healthcare IT leaders in terms of AI governance, data quality, and interoperability by mid-2026. A significant effort is being made to address data readiness challenges and to enhance health data exchange through a $1.3 million federal initiative. These topics are at the forefront of the industry's agenda to improve healthcare infrastructure and outcomes.

  • 01AI governance gaps are challenging healthcare IT leaders.
  • 02Data readiness is a critical concern in healthcare.
  • 03Federal funding is supporting health data exchange initiatives.

Jul 2, 2026

Healthcare Supply Chain Has a Board-Level Governance Problem.

Healthcare Supply Chain Has a Board-Level Governance Problem.

Healthcare providers recognize supply chain as a top financial lever, yet boards review it less than quarterly, creating a structural governance gap. This misalignment is driving 71% of organizations to replace or upgrade major supply chain applications within 24 months, with demand shifting toward integrated platforms that deliver board-level reporting and measurable ROI.

  • 0183% of healthcare supply chain professionals report board-level review occurs less than quarterly despite 90% ranking supply chain as a top-three financial lever
  • 0271% of health systems plan to replace or upgrade major supply chain applications in the next 24 months, driven by fragmented architectures and weak integration rather than platform failure
  • 03Healthcare supply chain management market projected to grow from $3.94 billion in 2026 to $6.52 billion by 2031, driven by modernization replacing legacy systems under margin pressure

Jun 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub